Compared to Estimates, Journey Medical (DERM) Q3 Earnings: A Look at Key Metrics

For the quarter ended September 2025, Journey Medical Corporation (DERM) reported revenue of $17.63 million, up 20.5% over the same period last year. EPS came in at -$0.09, compared to -$0.12 in the year-ago quarter.

The reported revenue represents a surprise of -0.39% over the Zacks Consensus Estimate of $17.7 million. With the consensus EPS estimate being -$0.08, the EPS surprise was -12.5%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Journey Medical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Total net product revenue- Accutane: $2.77 million compared to the $3.54 million average estimate based on two analysts. The reported number represents a change of -30.7% year over year.
• Total net product revenue- EmrosiTM: $4.88 million versus $6.35 million estimated by two analysts on average.
• Total net product revenue- Qbrexza: $7.36 million versus $6.67 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -2.9% change.

View all Key Company Metrics for Journey Medical here>>>

Shares of Journey Medical have returned +25.7% over the past month versus the Zacks S&P 500 composite's +4.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
Journey Medical Corporation (DERM): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research